Matthew Biegler
Stock Analyst at Oppenheimer
(1.80)
# 2,659
Out of 4,479 analysts
57
Total ratings
29.79%
Success rate
-8.22%
Average return
Main Sectors:
Top Industries:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNAC Cartesian Therapeutics | Downgrades: Peer Perform | n/a | $16.88 | - | 4 | Jul 2, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Outperform | $50 → $25 | $3.79 | +559.63% | 6 | Jun 18, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Outperform | $16 → $14 | $6.14 | +128.01% | 5 | May 14, 2024 | |
| VOR Vor Biopharma | Reiterates: Outperform | $15 → $10 | $0.92 | +986.84% | 6 | May 13, 2024 | |
| TYRA Tyra Biosciences | Reiterates: Outperform | $25 → $28 | $18.06 | +55.04% | 3 | May 13, 2024 | |
| RLAY Relay Therapeutics | Reiterates: Outperform | $33 → $25 | $6.06 | +312.54% | 4 | May 6, 2024 | |
| ELTX Elicio Therapeutics | Reiterates: Perform | n/a | $3.51 | - | 1 | Apr 1, 2024 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $14 → $17 | $7.46 | +127.88% | 2 | Mar 12, 2024 | |
| OLMA Olema Pharmaceuticals | Reiterates: Outperform | $21 | $10.57 | +98.68% | 3 | Mar 12, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 → $80 | $25.27 | +216.58% | 1 | Feb 28, 2024 | |
| FATE Fate Therapeutics | Reiterates: Perform | n/a | $3.20 | - | 3 | Feb 27, 2024 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Perform | n/a | $13.46 | - | 2 | Feb 27, 2024 | |
| BPMC Blueprint Medicines | Upgrades: Outperform | $85 | $109.50 | -22.37% | 4 | Oct 27, 2023 | |
| APTO Aptose Biosciences | Maintains: Outperform | $50 → $15 | $0.75 | +1,910.72% | 4 | Aug 11, 2023 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $30 → $35 | $34.60 | +1.16% | 2 | Aug 11, 2023 | |
| ACRV Acrivon Therapeutics | Initiates: Outperform | $25 | $5.93 | +321.59% | 1 | Jun 2, 2023 | |
| NKTX Nkarta | Downgrades: Perform | n/a | $5.80 | - | 3 | Dec 22, 2022 | |
| CELU Celularity | Downgrades: Perform | n/a | $3.06 | - | 2 | Dec 22, 2022 | |
| PRTG Portage Biotech | Maintains: Outperform | $26 → $18 | $0.18 | +10,006.68% | 1 | Nov 30, 2022 |
Cartesian Therapeutics
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $16.88
Upside: -
Zentalis Pharmaceuticals
Jun 18, 2024
Maintains: Outperform
Price Target: $50 → $25
Current: $3.79
Upside: +559.63%
Fulcrum Therapeutics
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $6.14
Upside: +128.01%
Vor Biopharma
May 13, 2024
Reiterates: Outperform
Price Target: $15 → $10
Current: $0.92
Upside: +986.84%
Tyra Biosciences
May 13, 2024
Reiterates: Outperform
Price Target: $25 → $28
Current: $18.06
Upside: +55.04%
Relay Therapeutics
May 6, 2024
Reiterates: Outperform
Price Target: $33 → $25
Current: $6.06
Upside: +312.54%
Elicio Therapeutics
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $3.51
Upside: -
ORIC Pharmaceuticals
Mar 12, 2024
Maintains: Outperform
Price Target: $14 → $17
Current: $7.46
Upside: +127.88%
Olema Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $21
Current: $10.57
Upside: +98.68%
Arvinas
Feb 28, 2024
Reiterates: Outperform
Price Target: $95 → $80
Current: $25.27
Upside: +216.58%
Fate Therapeutics
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $3.20
Upside: -
Day One Biopharmaceuticals
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $13.46
Upside: -
Blueprint Medicines
Oct 27, 2023
Upgrades: Outperform
Price Target: $85
Current: $109.50
Upside: -22.37%
Aptose Biosciences
Aug 11, 2023
Maintains: Outperform
Price Target: $50 → $15
Current: $0.75
Upside: +1,910.72%
IDEAYA Biosciences
Aug 11, 2023
Maintains: Outperform
Price Target: $30 → $35
Current: $34.60
Upside: +1.16%
Acrivon Therapeutics
Jun 2, 2023
Initiates: Outperform
Price Target: $25
Current: $5.93
Upside: +321.59%
Nkarta
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $5.80
Upside: -
Celularity
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.06
Upside: -
Portage Biotech
Nov 30, 2022
Maintains: Outperform
Price Target: $26 → $18
Current: $0.18
Upside: +10,006.68%